Inhibrx Historical Balance Sheet

INBX Stock

USD 14.35 0.25 1.77%

Trend analysis of Inhibrx balance sheet accounts such as Other Liabilities of 120.2 K or Net Tangible Assets of 70.1 M provides information on Inhibrx's total assets, liabilities, and equity, which is the actual value of Inhibrx to its prevalent stockholders. By breaking down trends over time using Inhibrx balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Inhibrx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inhibrx is a good buy for the upcoming year.

Inhibrx Inventory

(10.96 Million)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.

About Inhibrx Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Inhibrx at a specified time, usually calculated after every quarter, six months, or one year. Inhibrx Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Inhibrx and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Inhibrx currently owns. An asset can also be divided into two categories, current and non-current.

Inhibrx Balance Sheet Chart

At this time, Inhibrx's Other Current Liabilities is fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 70.1 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 28 M in 2025.

Other Current Liab Total Current Liabilities Other Liab Accounts Payable Short Term Debt

Add Fundamental

Total Current Liabilities

Total Current Liabilities is an item on Inhibrx balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Inhibrx are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Inhibrx obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Inhibrx are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Inhibrx's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Inhibrx current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.At this time, Inhibrx's Other Current Liabilities is fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 70.1 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 28 M in 2025.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	27.6M	56.3M	40.7M	28.0M
Other Current Liabilities	17.2M	43.9M	29.9M	31.4M

Total Current Liabilities Other Current Liab

Inhibrx balance sheet Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Current Assets	Total Current Assets	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Stockholder Equity	Total Liab	Net Invested Capital
Other Current Liab		0.94	-0.07	0.71	-0.78	0.69	0.2	0.85	0.16	0.87	0.57	0.78	0.74	-0.57	-0.82	0.86	0.81	0.92	0.86	-0.32	0.05	0.45	-0.21	0.88	0.61	0.83
Total Current Liabilities	0.94		0.11	0.62	-0.83	0.82	0.36	0.86	0.39	0.88	0.63	0.67	0.84	-0.41	-0.74	0.86	0.88	0.8	0.86	-0.3	0.19	0.56	-0.35	0.88	0.7	0.82
Other Liab	-0.07	0.11		-0.47	0.06	0.11	0.18	-0.16	0.69	-0.13	-0.03	-0.33	0.4	0.82	0.23	-0.15	0.25	-0.15	-0.15	-0.32	0.17	0.14	-0.17	-0.18	0.14	-0.24
Net Tangible Assets	0.71	0.62	-0.47		-0.57	0.68	0.46	0.77	0.12	0.78	0.41	0.93	0.55	-0.73	-0.89	0.78	0.6	0.71	0.78	-0.16	-0.12	0.18	-0.47	0.77	0.3	0.81
Retained Earnings	-0.78	-0.83	0.06	-0.57		-0.61	-0.19	-0.93	-0.22	-0.92	-0.94	-0.45	-0.54	0.43	0.48	-0.92	-0.57	-0.66	-0.92	0.11	-0.63	-0.87	0.14	-0.96	-0.93	-0.89
Accounts Payable	0.69	0.82	0.11	0.68	-0.61		0.63	0.73	0.63	0.76	0.44	0.72	0.84	-0.37	-0.78	0.75	0.84	0.61	0.75	-0.3	0.02	0.35	-0.62	0.71	0.48	0.7
Other Current Assets	0.2	0.36	0.18	0.46	-0.19	0.63		0.27	0.6	0.27	0.08	0.36	0.44	0.03	-0.38	0.27	0.32	0.0	0.27	-0.04	-0.09	0.0	-1.0	0.26	0.07	0.29
Total Current Assets	0.85	0.86	-0.16	0.77	-0.93	0.73	0.27		0.2	1.0	0.85	0.71	0.66	-0.59	-0.72	1.0	0.72	0.83	1.0	-0.35	0.36	0.73	-0.24	0.98	0.82	0.99
Property Plant Equipment	0.16	0.39	0.69	0.12	-0.22	0.63	0.6	0.2		0.23	0.12	0.16	0.7	0.45	-0.22	0.21	0.54	0.03	0.21	-0.1	0.17	0.17	-0.57	0.2	0.21	0.11
Total Assets	0.87	0.88	-0.13	0.78	-0.92	0.76	0.27	1.0	0.23		0.83	0.74	0.7	-0.59	-0.76	1.0	0.76	0.85	1.0	-0.37	0.32	0.71	-0.25	0.98	0.8	0.98
Short Long Term Debt Total	0.57	0.63	-0.03	0.41	-0.94	0.44	0.08	0.85	0.12	0.83		0.25	0.35	-0.33	-0.26	0.84	0.38	0.52	0.84	-0.2	0.76	0.97	-0.02	0.84	0.98	0.82
Total Stockholder Equity	0.78	0.67	-0.33	0.93	-0.45	0.72	0.36	0.71	0.16	0.74	0.25		0.68	-0.69	-0.99	0.73	0.74	0.83	0.73	-0.35	-0.35	0.05	-0.39	0.68	0.2	0.74
Property Plant And Equipment Net	0.74	0.84	0.4	0.55	-0.54	0.84	0.44	0.66	0.7	0.7	0.35	0.68		-0.09	-0.75	0.67	0.97	0.69	0.67	-0.45	-0.02	0.3	-0.44	0.64	0.43	0.6
Current Deferred Revenue	-0.57	-0.41	0.82	-0.73	0.43	-0.37	0.03	-0.59	0.45	-0.59	-0.33	-0.69	-0.09		0.65	-0.6	-0.27	-0.64	-0.6	0.06	0.17	-0.15	-0.02	-0.58	-0.23	-0.65
Net Debt	-0.82	-0.74	0.23	-0.89	0.48	-0.78	-0.38	-0.72	-0.22	-0.76	-0.26	-0.99	-0.75	0.65		-0.74	-0.82	-0.86	-0.74	0.41	0.35	-0.08	0.41	-0.7	-0.24	-0.74
Cash	0.86	0.86	-0.15	0.78	-0.92	0.75	0.27	1.0	0.21	1.0	0.84	0.73	0.67	-0.6	-0.74		0.73	0.84	1.0	-0.37	0.34	0.72	-0.25	0.98	0.81	0.99
Non Current Assets Total	0.81	0.88	0.25	0.6	-0.57	0.84	0.32	0.72	0.54	0.76	0.38	0.74	0.97	-0.27	-0.82	0.73		0.79	0.73	-0.49	-0.06	0.31	-0.33	0.68	0.45	0.67
Long Term Debt	0.92	0.8	-0.15	0.71	-0.66	0.61	0.0	0.83	0.03	0.85	0.52	0.83	0.69	-0.64	-0.86	0.84	0.79		0.84	-0.55	-0.08	0.4	-0.02	0.79	0.53	0.82
Cash And Short Term Investments	0.86	0.86	-0.15	0.78	-0.92	0.75	0.27	1.0	0.21	1.0	0.84	0.73	0.67	-0.6	-0.74	1.0	0.73	0.84		-0.37	0.34	0.72	-0.25	0.98	0.81	0.99
Net Receivables	-0.32	-0.3	-0.32	-0.16	0.11	-0.3	-0.04	-0.35	-0.1	-0.37	-0.2	-0.35	-0.45	0.06	0.41	-0.37	-0.49	-0.55	-0.37		0.24	-0.21	0.06	-0.19	-0.25	-0.38
Common Stock Shares Outstanding	0.05	0.19	0.17	-0.12	-0.63	0.02	-0.09	0.36	0.17	0.32	0.76	-0.35	-0.02	0.17	0.35	0.34	-0.06	-0.08	0.34	0.24		0.84	0.17	0.41	0.76	0.29
Non Current Liabilities Total	0.45	0.56	0.14	0.18	-0.87	0.35	0.0	0.73	0.17	0.71	0.97	0.05	0.3	-0.15	-0.08	0.72	0.31	0.4	0.72	-0.21	0.84		0.07	0.72	0.98	0.68
Inventory	-0.21	-0.35	-0.17	-0.47	0.14	-0.62	-1.0	-0.24	-0.57	-0.25	-0.02	-0.39	-0.44	-0.02	0.41	-0.25	-0.33	-0.02	-0.25	0.06	0.17	0.07		-0.23	-0.01	-0.27
Other Stockholder Equity	0.88	0.88	-0.18	0.77	-0.96	0.71	0.26	0.98	0.2	0.98	0.84	0.68	0.64	-0.58	-0.7	0.98	0.68	0.79	0.98	-0.19	0.41	0.72	-0.23		0.82	0.96
Total Liab	0.61	0.7	0.14	0.3	-0.93	0.48	0.07	0.82	0.21	0.8	0.98	0.2	0.43	-0.23	-0.24	0.81	0.45	0.53	0.81	-0.25	0.76	0.98	-0.01	0.82		0.77
Net Invested Capital	0.83	0.82	-0.24	0.81	-0.89	0.7	0.29	0.99	0.11	0.98	0.82	0.74	0.6	-0.65	-0.74	0.99	0.67	0.82	0.99	-0.38	0.29	0.68	-0.27	0.96	0.77

Click cells to compare fundamentals

Inhibrx Account Relationship Matchups

Inhibrx balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Other Current Liab	13.4M	9.6M	17.2M	43.9M	29.9M	31.4M
Total Current Liabilities	31.4M	22.5M	27.6M	56.3M	40.7M	28.0M
Other Liab	363K	2.9M	917K	110K	126.5K	120.2K
Net Tangible Assets	(93.6M)	75.5M	52.4M	58.1M	66.8M	70.1M
Retained Earnings	(145.4M)	(227.1M)	(372.4M)	(613.7M)	(106.1M)	(111.4M)
Accounts Payable	13.5M	9.1M	8.3M	8.3M	9.2M	7.2M
Other Current Assets	132.2M	7.8M	6.6M	16.7M	7.4M	7.0M
Total Current Assets	132.2M	139.1M	280.5M	295.4M	160.4M	130.1M
Property Plant Equipment	10.7M	11.3M	9.5M	2.5M	2.9M	2.7M
Total Assets	143.7M	150.5M	290.9M	307.9M	180.8M	155.0M
Short Long Term Debt Total	37.5M	72.1M	203.9M	210.1M	8.0M	7.6M
Total Stockholder Equity	75.5M	52.4M	58.1M	43.5M	133.6M	140.3M
Property Plant And Equipment Net	11.3M	9.5M	7.2M	9.4M	13.5M	9.1M
Current Deferred Revenue	7.9M	3.1M	2.0M	166K	149.4K	141.9K
Net Debt	(91.2M)	(60.8M)	(71.8M)	(67.8M)	(144.5M)	(137.3M)
Cash	128.7M	131.3M	273.9M	277.9M	152.6M	136.3M
Non Current Assets Total	11.6M	11.3M	10.4M	12.5M	20.4M	11.4M
Long Term Debt	29.2M	70.5M	202.1M	207.0M	238.0M	249.9M
Cash And Short Term Investments	128.7M	131.3M	273.9M	277.9M	152.6M	136.3M
Net Receivables	615K	878K	257K	778K	397K	474.9K
Common Stock Shares Outstanding	25.3M	38.0M	40.1M	47.1M	15.0M	14.2M
Liabilities And Stockholders Equity	143.7M	150.5M	290.9M	307.9M	180.8M	155.0M
Non Current Liabilities Total	36.9M	75.6M	205.2M	208.1M	6.5M	6.1M
Capital Lease Obligations	8.2M	6.7M	5.0M	3.2M	8.0M	5.4M
Inventory	(129.3M)	(878K)	(257K)	(11.6M)	(10.4M)	(11.0M)
Other Stockholder Equity	220.8M	279.5M	430.4M	657.2M	239.7M	242.9M
Total Liab	68.3M	98.1M	232.8M	264.4M	47.2M	44.8M
Net Invested Capital	104.7M	70.5M	260.1M	250.5M	133.6M	95.9M
Property Plant And Equipment Gross	11.3M	3.2M	2.5M	16.1M	22.4M	23.6M
Net Working Capital	100.8M	116.7M	252.9M	239.0M	119.7M	112.8M
Short Term Debt	1.5M	1.7M	1.9M	4.1M	1.6M	2.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inhibrx Historical Balance Sheet

Inhibrx Inventory

(10.96 Million)

About Inhibrx Balance Sheet Analysis

Inhibrx Balance Sheet Chart

Total Current Liabilities

Accounts Payable

Inhibrx balance sheet Correlations

Inhibrx Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inhibrx balance sheet Accounts

Also Currently Popular

Additional Tools for Inhibrx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Assets	+ 1.0	Total Current Assets
Cash	+ 1.0	Total Current Assets
Cash And Short Term Investments	+ 1.0	Total Current Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash

Inventory	- 1.0	Other Current Assets
Net Debt	- 0.99	Total Stockholder Equity
Other Stockholder Equity	- 0.96	Retained Earnings
Short Long Term Debt Total	- 0.94	Retained Earnings
Total Liab	- 0.93	Retained Earnings
Total Current Assets	- 0.93	Retained Earnings